KNect365 is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


OSE Immunotherapeutics seeks partner for lead drug

Scrip chats with Alexis Peyroles, chief operating officer of OSE Immunotherapeutics, on the sidelines of the recent BIO-Europe® partnering meeting about the company's plans for commercializing lead drug, Tedopi (OSE-2102). Based in France, OSE Immunotherapeutics is a biotechnology company developing innovative immunotherapies that act on effector and suppressor cells to stimulate or inhibit the body's immune response, and to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation. Tedopi, the company’s most advanced pipeline product, is currently in Phase III for non-small cell lung cancer.

Get the latest news as it happens.